Brief: Selecta Biosciences Provides Business Update And Outlook For 2023

Cartesian Therapeutics

09/01/2023 13:13

Jan 9 (Reuters) - Selecta Biosciences Inc  SELB.O :
    * SELECTA BIOSCIENCES PROVIDES BUSINESS UPDATE AND OUTLOOK
FOR
2023
    * SELECTA BIOSCIENCES INC - EXPECTED TOPLINE DATA FOR PHASE
3
DISSOLVE I & II PROGRAMS OF SEL-212 IN CHRONIC REFRACTORY GOUT
IN Q1 2023
    * SELECTA BIOSCIENCES - TO RECEIVE $10 MILLION UPFRONT FOR
EXECUTION OF A LICENSE AGREEMENT FOR XORK, TO BE DEVELOPED WITH
ASTELLAS GENE THERAPIES' AT845

Source text for Eikon:  ID:nGNX8dzWyF 
Further company coverage:  SELB.O 
 ((Reuters.Briefs@thomsonreuters.com;))